https://www.socictopen.socict.org/files/original/5248ecd25241436b8c3d63c2b8a4d9e9.pdf 4bd122267004db24b6b33fb61ec5d1a1 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia Creator An entity primarily responsible for making the resource Francesco Ferrara, Giovanni Granata, Antonio Vitiello, Raffaele Laporta, Chiara Pelliccia Description An account of the resource For some patients with SARS-CoV-2, the worst clinical damage is not caused by the virus itself, but by an overactive inflammatory state. In fact, in some people the immune system goes into overdrive and launches a large-scale assault on the tissue known as cytokine storm. This excessive inflammatory/immune reaction can damage tissue and eventually kill people. Evidence shows that blocking such cytokine storms can be effective and trials are underway to test drugs that act by reducing cytokine response, such as tocilizumab and sarilumab which bind interleukin 6 (IL-6), or anikinra which is the interleukin 1 receptor antagonist (IL-1). However, other drugs that block the cytokine cascade can also be considered. In this article we describe the scientific and molecular motivation for the use of drugs that act by modulating the hyperactive inflammatory system in severe patients suffering from SARS-CoV-2, considering in particular an old drug that has been in use for many years for other therapeutic indications such as colchicine, and that could be favourable to its use, with low cost and good tolerability. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource immunology, infection, cytokine, Colchicine, SARS-CoV-2, COVID-19 Identifier An unambiguous reference to the resource within a given context DOI: 10.4081/itjm.2020.1284 Source A related resource from which the described resource is derived Italian Journal of Medicine Publisher An entity responsible for making the resource available PAGEPress Publications Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine